UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Adds five years of market exclusivity on approval
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
The country is sixth among the most affected countries by active cases
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Ind-Ra expects revenue growth of over 12% in 2022.
Subscribe To Our Newsletter & Stay Updated
